285 related articles for article (PubMed ID: 30268576)
1. Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences.
Falagas ME; Athanasaki F; Voulgaris GL; Triarides NA; Vardakas KZ
Int J Antimicrob Agents; 2019 Jan; 53(1):22-28. PubMed ID: 30268576
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo functional activity of Chlamydia MurA, a UDP-N-acetylglucosamine enolpyruvyl transferase involved in peptidoglycan synthesis and fosfomycin resistance.
McCoy AJ; Sandlin RC; Maurelli AT
J Bacteriol; 2003 Feb; 185(4):1218-28. PubMed ID: 12562791
[TBL] [Abstract][Full Text] [Related]
3. Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and
Zheng D; Bergen PJ; Landersdorfer CB; Hirsch EB
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0144621. PubMed ID: 34807759
[TBL] [Abstract][Full Text] [Related]
4. New perspectives for reassessing fosfomycin: applicability in current clinical practice.
Candel FJ; Matesanz David M; Barberán J
Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):1-7. PubMed ID: 31131586
[TBL] [Abstract][Full Text] [Related]
5. Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal
Ito R; Mustapha MM; Tomich AD; Callaghan JD; McElheny CL; Mettus RT; Shanks RMQ; Sluis-Cremer N; Doi Y
mBio; 2017 Aug; 8(4):. PubMed ID: 28851843
[TBL] [Abstract][Full Text] [Related]
6. Fosfomycin: Mechanism and Resistance.
Silver LL
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28062557
[TBL] [Abstract][Full Text] [Related]
7. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
Stock I
Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
[TBL] [Abstract][Full Text] [Related]
8. Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
Hickman RA; Hughes D; Cars T; Malmberg C; Cars O
Clin Microbiol Infect; 2014 Apr; 20(4):O267-73. PubMed ID: 24118201
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
Demir T; Buyukguclu T
Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility to fosfomycin of hospital strains isolated in Nantes (France). Frequency of mutation to resistance.
Courtieu AL; Drugeon H; Billaudel S
Chemotherapy; 1977; 23 Suppl 1():25-36. PubMed ID: 401717
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial Susceptibility and Molecular Mechanisms of Fosfomycin Resistance in Clinical Escherichia coli Isolates in Mainland China.
Li Y; Zheng B; Li Y; Zhu S; Xue F; Liu J
PLoS One; 2015; 10(8):e0135269. PubMed ID: 26252888
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Mavromanolakis E; Samonis G
Int J Antimicrob Agents; 2010 Mar; 35(3):240-3. PubMed ID: 20034765
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Fosfomycin Activity Against Extended Spectrum Beta Lactamase (ESBL) Producing Enterobacteriaceae Isolated from Three Centers of Tehran, Iran.
Ghanavati R; Ohadi E; Kazemian H; Yazdani F; Torki A; Kalani BS; Irajian G
Recent Pat Antiinfect Drug Discov; 2018; 13(2):180-186. PubMed ID: 29769010
[TBL] [Abstract][Full Text] [Related]
14. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
Falagas ME; Kastoris AC; Karageorgopoulos DE; Rafailidis PI
Int J Antimicrob Agents; 2009 Aug; 34(2):111-20. PubMed ID: 19403273
[TBL] [Abstract][Full Text] [Related]
15. Fosfomycin: Resurgence of an old companion.
Sastry S; Doi Y
J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259
[TBL] [Abstract][Full Text] [Related]
16. The revival of fosfomycin.
Michalopoulos AS; Livaditis IG; Gougoutas V
Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
[TBL] [Abstract][Full Text] [Related]
17. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria.
Dinh A; Salomon J; Bru JP; Bernard L
Scand J Infect Dis; 2012 Mar; 44(3):182-9. PubMed ID: 22176655
[TBL] [Abstract][Full Text] [Related]
18. Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.
Rodríguez-Rojas A; Maciá MD; Couce A; Gómez C; Castañeda-García A; Oliver A; Blázquez J
PLoS One; 2010 Apr; 5(4):e10193. PubMed ID: 20419114
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli.
Takahata S; Ida T; Hiraishi T; Sakakibara S; Maebashi K; Terada S; Muratani T; Matsumoto T; Nakahama C; Tomono K
Int J Antimicrob Agents; 2010 Apr; 35(4):333-7. PubMed ID: 20071153
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Fosfomycin Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolates from Human and Pig in Taiwan.
Tseng SP; Wang SF; Kuo CY; Huang JW; Hung WC; Ke GM; Lu PL
PLoS One; 2015; 10(8):e0135864. PubMed ID: 26280832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
